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cetuximab conjugated with 
octreotide and entrapped calcium 
Alginate-beads for targeting 
Somatostatin Receptors
Ahmed A. H. Abdellatif  1,2*, Mohamed A. ibrahim2,3, Mohammed A. Amin1,2, 
Hamzah Maswadeh1, Muhammed N. Alwehaibi4, Sultan N. Al-Harbi4, Zayed A. Alharbi4, 
Hamdoon A. Mohammed  5,6, Ahmed B. M. Mehany7 & imran Saleem  8
There is a need to formulate oral cetuximab (CTX) for targeting colorectal cancer, which is reported to 
express somatostatin receptors (SSTRs). Therefore, coating CTX with a somatostatin analogue such as 
octreotide (OCT) is beneficial. Alginate was used to coat CTX to facilitate delivery to the gastrointestinal 
tract (GIT). This study aimed to deliver CTX conjugated with OCT in the form of microparticles as a 
GIT-targeted SSTR therapy. Both CTX and OCT were conjugated using a solvent evaporation method 
and the conjugated CTX-OCT was then loaded onto Ca-alginate-beads (CTX-OCT-Alg), which were 
characterized for drug interactions using differential scanning calorimetry (DSC), and Fourier transform 
infrared spectra (FTIR). Moreover, the morphology of formulated beads was examined using a scanning 
electron microscope (SEM). The drug content and release profile were studied using UV spectroscopy. 
Finally, in vitro cytotoxicity of all compounds was evaluated. The results showed homogenous 
conjugated CTX-OCT with a diameter of 0.4 mm. DSC showed a delay in the OCT peak that appeared 
after 200 °C due to small polymer interaction that shifted the OCT peak. Moreover, FTIR showed no 
prominent interaction. SEM showed clear empty cavities in the plain Ca-alginate-beads, while CTX-
OCT-Alg showed occupied beads without cavities. CTX-OCT-Alg had a negligible release in 0.1 N HCl, 
while the CTX-OCT was completely released after 300 min in phosphate buffer pH 7.4. All formulations 
showed good antiproliferative activity compared with free drugs. The formulated CTX-OCT-Alg are a 
promising platform for targeting colorectal cancer through Git.
Oral dosage forms of medications are generally a convenient dosage form for drug delivery1,2. However, one 
of the main challenges in drug delivery is to overcome gastric barriers and preventing the drug release in the 
stomach3. There was a huge increase in the development of orally delivered anti-cancer agents in the past 10 
years, as a quarter of all available anti-cancer drugs are now administered orally4. Colorectal cancer is one of the 
most common forms of malignancy and the fourth most common contributor to cancer mortalities5. Moreover, 
targeting specific cells in cancer therapy provides an advantageous way to treat cancer directly6–10. For example, 
the release of drug in the colon and drug particles can be driven by octreotide (OCT) and bind to somatostatin 
receptors (SSTRs), which are a component of ligand-mediated targeting8. The inhibition effect of somatostatin 
(SST) analogues on tumor cells is one effective approach to cancer therapy. Moreover, SST and its analogues have 
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shown proliferative inhibition of colon cancer cell lines11. There are five subtypes of SSTRs expressed in colorectal 
cancer, and SSTR1 is the most prevalent compared to the others12.
Cetuximab (CTX) is a recombinant monoclonal antibody drug used in the management and treatment of 
colorectal cancer. It is currently only administered intravenously, but there is a need for an oral administered CTX 
because of the adverse effects such as cardiopulmonary arrest, hypotension, bronchospasm, and dermatological 
toxicity13,14. Cancer development is promoted by EGFR-induced cell growth, migration, and survival15. Targeted 
therapy is a good method for the management of colorectal cancer through the use of “epidermal growth factor 
receptor inhibitors” (EGFR), such as CTX, which is linked to oral squamous cell carcinoma patient survival16. 
CTX is a chimeric monoclonal antibody that binds to EGFR and inhibits EGFR tyrosine kinase activity, which in 
turn suppresses EGFR-positive cancer development17.
The SSTRs are G-protein-coupled receptors6–10, which are expressed in numerous neuroendocrine cancers, 
including colorectal cancers. They can be targeted with cyclic octapeptides such as octreotide, which is a deriva-
tive of native SST. Hence, the conjugation of cargos to octreotides suggests an intelligent approach to cancer treat-
ment18. Lelle et al. presented a modern approach to drug-carrier conjugate in a site-specific manner providing 
excellent versatility and allowing stimulated release within cancer cells. They developed doxorubicin-octreotide 
bioconjugate for overexpressed SSTRs in tumor cells, where the first cleavable disulphide-intercalating connector 
was the binding between the two elements. The findings demonstrated the delivery platform in biological settings 
of cytotoxicity studies within cell lines for pancreatic, pituitary, and breast cancer19. Hence, selective targeting of 
the SST receptor expressed on colorectal cancer cells can be achieved by conjugating CTX to OCT, which guides 
CTX directly to colorectal cancer cells. OCT is a somatostatin analogue commonly used as an anti-cancer agent 
that targets SSTRs in the GIT that are expressed in colon cancer. However, OCT also has some side effects that are 
associated with its IV administration, such as local itching at the site of injection14,20. Therefore, oral delivery of 
OCT is an alternative and can enhance the therapeutic activity of CTX orally21.
Alginate is naturally found in brown seaweed and can form biodegradable and inert hydrogels that provide 
safe, orally controlled release22. It can deliver drugs and target the colon, and is pH-sensitive, which can aid the 
controlled release of a drug within a pH 7.4 environment such as Small intestines or colon. Sodium alginate is 
capable of forming a hydrogel through conjugation with divalent calcium cations (Ca2+). Furthermore, the for-
mulation of a drug in the formulated Ca-alginate-beads has many advantages, such as avoiding gastric irritation 
and providing controlled release of the drug via oral administration due to swelling in the colon rather than in the 
stomach23. Many findings have exhibited the benefit of Ca-alginate-beads in controlling drug release. For exam-
ple, rifampicin was loaded into Ca-alginate-beads and released in a buffer solution of pH 7.4 but not in a solution 
of pH 1.224. Another study indicated targeting to the colon through encapsulation of mebendazole using alginate, 
which provided prolonged colon release of more than 12 hr25. Finally, Ca-alginate-beads delivered an anti-cancer 
agent such as etoposide or that avoided the systemic adverse effects of chemotherapeutic agents and provided 
targeted, controlled treatment with reduced cytotoxicity26.
Colon targeted therapy is widely helpful not only for localized colon cancer treatment but also for the deliv-
ery of drugs that are inactivated by acidic pH2. Moreover, colonic delivery can be successfully achieved through 
protecting the drug from gastric release, with a release in the colon at an optimum pH2,27–29. However, alginate 
polymers alone have some limitations, including low mechanical stability, which may facilitate the release and 
swelling of alginate polymer more rapidly30. This study aimed to provide oral colonic targeted therapy using 
OCT-conjugated CTX to avoid systemic side effects. CTX was conjugated with OCT in Ca-alginate-beads for tar-
geting SSTRs expressed in colorectal cancer. The final formulation was characterized by particle size, DSC, FTIR, 
in vitro release of the formulated CTX-OCT-Alg at phosphate buffer pH 7.4, and cytotoxic activity.
Results and discussion
preparation of the conjugated ctX with oct. This study aimed to formulate CTX conjugated with 
OCT in Ca-alginate-beads using sodium alginate polymer for targeting of SSTRs expressed in colorectal cancer. 
Due to differences in the solubility of OCT and CTX, CTX was coated with OCT forming a soluble CTX-OCT 
product. OCT is a water-soluble drug, while CTX is soluble in a mixture of methanol and chloroform, forming 
a clear rather than a cloudy solution. We found one study which used polyethylene glycol (PEG) as a coating 
polymer for fluconazole in water to exploit the hydrophilicity of PEG; the fluconazole and PEG reaction was 
carried out by solvent evaporation to form highly soluble fluconazole28. The CTX was converted from a water-in-
soluble material to highly water-soluble CTX-OCT particles that facilitated the transfer of CTX to the receptor 
site of SSTRs. Moreover, CTX was measured spectrophotometrically at a wavelength of 360 nm, while OCT was 
measured at 291 nm. It was previously reported that the CTX absorbance could be measured using a multiwall 
scanning spectrophotometer at 440 nm31, while OCT could be detected at 220 nm32. The variance between the 
published wavelength and our method could be due to the difference in the type of instruments used.
The formed Ca-alginate-beads before and after drying were studied at concentrations of 16, 22, 35, 60, and 
82 µM, all of which showed uniform beads before drying. However, after drying the beads were irregular in shape 
and did not hold their form (Fig. 1a–j). A concentration of 128 µM (30 mL sodium alginate/10 mL water) pro-
duced the most well-formed and stable beads before and after drying (Fig. 1k–n). The formed CTX-OCT particles 
were loaded into Ca-alginate-beads of uniform shape and size, which could be targeted to the GIT in treatment 
of colorectal cancer.
The encapsulation efficiency of the obtained CTX-OCT-Alg. The encapsulation efficiency of 
CTX-OCT in the Ca-alginate-beads ranged between 40–65% for the OCT and between 38–56% for the CTX. 
Table 1 shows the amount (mg) of CTX and OCT loaded in Ca-alginate-beads. The amount of OCT loaded 
was 4.5 ± 0.56 mg/10 mg OCT-beads, and 5.9 ± 0.61 mg/10 mg in CTX-OCT-beads, respectively. In addition, 
the amount of CTX loaded was 6.1 ± 0.91 mg/10 mg CTX-beads and 4.1 ± 0.34 mg/10 mg in CTX-OCT-Alg, 
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respectively. The amount of CTX and OCT loaded into CTX-OCT-Alg were reasonable as the amount initially 
used in the formulation was considered to be the saturated solution of CTX-OCT33.
Size, morphology and swelling determination. The formed beads at a concentration of 128 µM alginate 
were characterized to determine bead size. The prepared beads were measured at a resolution of 1.5× to determine 
the diameter of beads on a slide marked with 100-µm squares. The formulated beads were equal to four squares 
Figure 1. Ca-alginate and CTX-OCT-Alg before and after drying using different concentrations of sodium 
alginate. (a,b) plain Ca-alginate-beads (16 µM); (c,d) dried plain Ca-alginate-beads (22 µM); (e,f) dried plain 
Ca-alginate-beads (35 µM); (g,h) dried plain Ca-alginate-beads (60 µM); (i,j) dried plain Ca-alginate-beads 
(82 µM); (k,l) dried plain Ca-alginate-beads (128 µM; (m,n) dried CTX-OCT-Alg (128 µM).
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in width and height, with a diameter of 0.4 mm (Fig. 2), which was calculated as 4 squares × 100 µm = 400 µm. 
Another study found that formulated Ca-alginate-beads had diameters that ranged from 700 to 1400 μm34. This 
difference in size was due to the different formulation methods, in this study alginate was dropped into the CaCl2 
solution, whilst the grinded beads showed ranged size of 1–2 µm.
CTX free drug was imaged using SEM and observed to be composed of heterogeneous particles (Fig. 3a,b). 
However, after conjugation of CTX to OCT, the particles were homogenous (Fig. 3c,d), which confirmed the 
coating of CTX with OCT. Moreover, plain beads were imaged using at magnifications 35×, 500 µm and 140×, 
100 µm. In these images, the powders had empty cavities (Fig. 3e,f). In contrast, Ca-alginate-beads loaded with 
CTX-OCT powders had turbid and fill cavities, which indicated the physical presence of drug powder (Fig. 3g,h). 
Another study that used SEM to evaluate alginate bead shape found an irregular shape of sodium alginate before 
coating, that resolved to a homogenous and uniform shape after coating28, which was consistent with our findings 
(Fig. 3). This indicates that CTX alone does not confer irregular alginate bead structure, but after its conjugation 
with OCT, the beads take on a uniform and homogenous shape, which serves as an indication that OCT coating 
of CTX results in uniform structures.
TEM evaluation was used to examine the internal structure and morphology of CTX-OCT-Alg. The beads 
before milling exhibited irregular shapes with particle sizes <0.4 mm (Fig. 4). The internal structure of the CTX 
particles had no core (i.e. drug loading/encapsulation efficiency) and therefore, no distinct shape (Fig. 4a). After 
the CTX was coated with a layer of the stabilizing OCT, the particles were stable and soluble, and the CTX had a 
visible coating layer of OCT (Fig. 4b). TEM of CTX-OCT-Alg confirmed that CTX-OCT formed complexes and 
were incorporated inside the beads (Fig. 4c). Similar results were reported by Page et al., who showed vesicle-like 
shapes inside beads incorporated drugs35.
entrapment and drug interaction of ctX-oct in ca-alginate-beads. The thermal analysis of 
sodium alginate showed a broad endothermic peak that began at 145.5 °C, which indicated that the compound 
was pure. Moreover, the same peak was observed in the physical mixture of CTX-OCT (Fig. 5d). Pure OCT pow-
der produced an endothermic peak at 123 °C that ended at 168 °C, which represented the melting point of OCT 
(Fig. 5b). The pure CTX drug had an endothermic peak that began at 56 °C and it ended at 91.4 °C; these peaks 
indicated the melting point of CTX (Fig. 5c). We then analyzed Ca-alginate-beads and observed approximately 
the same endothermic peak as sodium alginate (Fig. 5a), which indicated no interaction between CTX-OCT 
conjugate and sodium alginate and indicate the CTX-OCT can be released from Ca-alginate-beads. DSC analysis 
of CTX-OCT-Alg showed endothermic peaks at 77.71 °C that represented CTX and a delay in the OCT peak that 
appeared after 200 °C, indicating a slight polymer interaction that shifted the OCT peak from 150 °C to 200 °C, 
this predicted reaction led us for formulate CTX-OCT (Fig. 5d).
To examine the drug interaction between OCT and CTX, FTIR was used. Absorption bands showed no prom-
inent interaction between the two compounds, and CTX-OCT bead powder had similar absorption bands as their 
raw powders. Bands between 3000–3600 cm−1 indicated O-H stretching in alginic acid, and OH in OCT. Bands 
Beads Sample
Amount of drug (mg) in 10 mg beads ± SD
Octreotide (OCT) Cetuximab (CTX)
Octreotide-beads 4.5 ± 0.56 —
Cetuximab-beads — 6.1 ± 0.91
Cetuximab-octreotide-beads 5.9 ± 0.61 4.1 ± 0.34
Table 1. Amount of drug loaded into Ca-alginate-beads measured using the wavelengths of octreotide and 
cetuximab.
Figure 2. Cetuximab-Octreotide alginate bead image using an Ultracut UCT Ultra-microtome (a) Cetuximab-
octreotide bead with visible measurement box markings (b) Cetuximab-octreotide bead without visible 
metered boxes.
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between 1670 and 1460 cm−1 were related to asymmetrical and symmetrical stretching vibrations of carboxylate 
salt ions in alginate and OCT. C-H stretching was presented at a range of 2955–2870 cm−1, while C-O stretching 
of the pyranose ring in alginate and OCT appeared at 1100 cm−1. Ca-alginate had a narrow O-H band compared 
to sodium alginate due to a decrease in OH groups from Ca-alginate chelation. The Ca ion substitution of the 
sodium ion resulted in a change in atomic weight and charge density; thus, asymmetric stretching vibrations were 
shifted to a lower wavelength (Fig. 6). Moreover, the FTIR studies showed no interaction between the CTX, OCT, 
Figure 3. Scanning Electron Microscopy of (a,b) cetuximab alone, (c,d) cetuximab-octreotide conjugation, 
(e) Plain beads at 35×, 500 µm (f) 140×, 100 µm, (g) cetuximab-octreotide beads at 35 × 500 µm, and (h) 
cetuximab-octreotide beads at 35 × 500 µm.
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and alginate, which was consistent with other results that used FTIR to confirm the physical interaction of all 
components but found no interaction between CTX, OCT and alginate32,36.
Alginic acid is an anionic polymer, hence the carboxyl groups are not ionized at a pH lower than the pKa, 
swelling of Ca-alginate beads is negligible under an acidic condition. Any product release thus mostly is due to 
Figure 4. Transmission Electron Microscope (a) the plain cetuximab, (b) cetuximab coated octreotide, and (c) 
cetuximab-octreotide incorporated beads. Scale bar is 500 µm.
Figure 5. Differential scanning calorimetry of (a) Ca-alginate-beads, (b) octreotide, (c) cetuximab, (d) 
cetuximab-octreotide-alginate-beads.
Figure 6. Cetuximab-octreotide raw powder and beads powder analysis through Fourier-transform infrared 
spectroscopy.
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the distribution of the medication over the insoluble matrix. Nevertheless the anionic polymer is more ionized 
and swells under neutral and basic conditions after which drug release is dependent on the beads’ swelling37. Bead 
swelling percent in HCl showed that very low change in diameter, which indicated a very low swelling percent-
age. In contrast, beads in phosphate buffer showed a gradual increase in diameter size, indicating a high swelling 
percentage (Table 2).
Release of ctX-oct from ca-alginate-beads. The release of CTX-OCT from Ca-alginate-beads relied 
on the diffusion of the release medium into the Ca-alginate-beads, swelling and dissolution of the alginate matrix. 
During the first 60 min in acidic media, none of the formulations released the drug compound. After this initial 
time, the release rates between the formulations were statistically significant (p < 0.05) in alkaline media, pH 
7.4 (Fig. 7). In the alkaline medium, the release of both OCT and CTX was biphasic, in which an initial burst 
was detected after pH changed, followed by a sustained release pattern. During the first stage after pH change 
(60–90 min), two superficial mechanisms, swelling and diffusion, control drug release from the beads. During the 
second phase from 90–300 min, the enlargement of the beads was continuous while did not affect drug release. 
Comparing the drug release from free and loaded beads, the alginate significantly reduced the release profile of 
the drug from beads. These results show that the free drugs were completely dissolved in the first 30 min in acidic 
pH, which justifies the role of alginate as a coat that can significantly increase the targeting and release of drug 
in GIT.
Once exposed to acidic media, Ca-alginate-beads tend to shrink. The carboxylates of the Ca-alginate-beads 
are protonated at low pH values (<4), which decreases and shrinks the electrostatic repulsion between these 
groups38,39. In addition, the swelling/bruising curve begins to decline in the somewhat basic PBS environment, 
implying dissolution or decay40. Additional, swelling/bruising of the dried beads was typically due to the hydra-
tion of the hydrophilic groups of alginate41. In this case, free water penetrates the beads and thus promotes a 
bigger swelling level, filling the inert pores among the polymer chains while no swelling was observed in acidic 
media. In the mild alkaline environment of PBS, all preparatory products showed significant swelling levels. In 
this case, the swelling was associated with the exchange of Ca2+ and ion Na+.40.
CTX-OCT’s alginate-bead release profile of 0.1 N HCl, pH 1.2 is shown in (Fig. 7), with 5.5% and 18.8% of 
the drug content discharged, in CTX-loaded and OCT-loaded-beads, respectively after 1 hr. The OCT powder 
in the acidic medium in comparison showed full release of the drug content after 1 hr. The highest peak of CTX 
release after 300 minutes was 64.2% and 95.7% of OCT. Zero-Order, First Order, Hixson–Crowell and Higuchi 
equations were used for the analysis of the separation kinetics and the process of the liberation of drugs from 
prepared Ca-alginate-beads. Table 3 shows that the release kinetics were better suited to the first-order equation 
and that the release rates were dependent on concentration. Furthermore, the mechanism by which OCT and 
Time 
(min)
Bead Diameter in HCl 
pH 1.2 (mm)
Bead Diameter in phosphate 
buffer pH 7.4 (mm)
0 0.4 0.4
30 0.41 0.45
60 0.41 0.45
90 0.42 0.55
120 0.43 0.60
150 0.44 0.65
180 0.44 0.70
210 0.45 0.80
240 0.45 Swell and burst
Table 2. Diameter size differences between plain beads dissolved in HCl and phosphate buffer, pH 7.4.
Figure 7. In vitro release of cetuximab-octreotide beads and raw powders. Free octreotide (blue line), free 
cetuximab (red line), cetuximab-octreotide according to octreotide (green line), and cetuximab-octreotide 
according to cetuximab (orange line). The results were expressed as the mean standard deviation of triplicate 
data in a single experiment.
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CTX were released from the Ca-alginate-beads produced in this study was best suited to the Hixson-Crownell 
equation. Previous studies reported that the release of drugs from Ca-alginate-beads was best fit to the Higuchi 
equation42,43, which characterized the mechanism of release as diffusion-controlled.
One of the limitations of formulating CTX-OCT in Ca-alginate-beads is the low mechanical stability 
of the beads, which may enhance the swelling of the alginate polymer and accelerate drug release. Coating 
Ca-alginate-beads with cationic polymers can overcome this problem low mechanical stability. Our in vitro 
release results showed that CTX-OCT-Alg have a low drug release rate after 60 min in 0.1 HCl 1.2 pH, while 
in phosphate buffer pH 7.4, all drug contents were released after 300 min. Results from flurbiprofen loaded 
Ca-alginate showed less than 5% of the drug content was released after 1 hr23, which support our finding that 
CTX release in 0.1 HCL 1.2 pH was less than 5% of drug content released after 1 h; however, OCT drug released 
was higher but still less than 20%. CTX-OCT-Alg in phosphate buffer 7.4 revealed a gradual increase of the drug 
release rate until complete release after 5 h. This finding agrees with the data from theophylline coated by alginate 
for colon targeting delivery, which had complete drug release after 7 h. This delay in release was attributed to the 
coating of Ca-alginate-beads with another polymer such as chitosan, which provided more release control com-
pared to our results with CTX-OCT-loaded beads44.
The mechanistic pathway of Ca-alginate-beads containing CTX-OCT can interpreted by swelling of 
Ca-alginate-beads then releasing of CTX-OCT in GIT medium. The CTX-OCT particles can be uptake through 
receptor activation within a mammalian cell. CTX-OCT can be internalize through endocytic vesicles by both 
phagocytosis and pinocytosis pathways45. Phagocytes are the more favored mechanism which can take up large 
particles (also, aggregates), or particles with certain ligand such as OCT. Moreover, the non-accepted mechanism 
for particles internalization in a non-phagocytic mammalian cell is commonly throughout pinocytosis or direct 
diffusion. Furthermore, particles can be taken up via specific internalization (receptor-mediated) endocytosis 
or nonspecific endocytosis45. The receptor-mediated endocytosis authorizes an introduction of extracellular big 
molecules (Fig. 8)46,47. In this phase, complex membrane micro-domains containing clathrins or caveolin-coated 
pits shape the plasma membrane47. Nevertheless, the precise absorption of nanoparticles through means of sur-
face receptors can be improved either through direct interactions between coated particles and receptors or via 
nanoparticles ligands47–49.
Determination of the antiproliferative activity of CTX-OCT formulations. The effects of tested 
compounds on human cancer cell lines HCT-116, HepG-2, and MCF-7 were measured and recorded in Table 4. 
The viability of the cells treated with OCT-alginate and CTX-alginate-beads significantly decreased compared 
to the free OCT and CTX treatments. This result could be due to the improved solubility of the OCT-alginate 
and CTX-alginate-beads, which improved cell penetration for both OCT and CTX in all cell lines as the anti-
proliferative activity for both OCT and CTX were improved50,51. For example, the HCT-116 cell line had an 
IC50 for OCT-alginate and CTX-alginate-beads of 5.48 µg/mL and 4.38 µg/mL vs 7.92 µg/mL and 5.21 µg/mL for 
free OCT and CTX, respectively. In addition, HEPG-2 cells showed a distinct reduction in the IC50 of OCT 
and CTX-alginate-beads (IC50 = 5.76 µg/mL and 3.82 µg/mL, respectively) compared to free OCT and CTX 
(IC50 = 10.26 µg/mL and 7.32 µg/mL, respectively). However, the outcomes exhibited less cytotoxic activity for 
CTX-OCT-Alginate-beads paralleled to the OCT-alginate or CTX-alginate-beads in all the tested cell lines50,51. 
These results suggest the coating of CTX with OCT decreased CTX activity by making a barrier layer around 
the molecules. Furthermore, CTX-OCT-Alginate-beads had the same activity as free CTX and were more active 
than free OCT. These findings indicate that the Ca-alginate-beads loaded with CTX-OCT can target the specific 
area in GIT at pH 7.4, allowing CTX-OCT to enter cells that express the SSTRs and then dissociate into OCT and 
CTX with anti-cancer activity. Importantly, the activities of all formulations were synergistic or similar to the free 
drugs, indicating that the anti-cancer activity was not affected by the alginate bead coating.
Materials and Methods
Materials. Cetuximab and OCT were purchased from Hong Kong Yuancheng Saichuang Technology 
Co. Limited (Hong Kong, China). Alginic acid sodium salt high viscosity grade A was purchased from MP 
Biomedicals (Eschwege, Germany). Calcium chloride (CaCl2), 99.5% methanol, hydrochloric acid, and diba-
sic sodium phosphate heptahydrate were purchased from Loba Chemie Pve. (Mumbai, India). Chloroform was 
purchased from Techno Pharmchem (Haryana, India). The mammary gland breast cancer cell line (MCF-7), 
Brand
Zero-order 
dissolution 
rate constant
First-order 
dissolution rate 
constant
Higuchi 
dissolution 
rate constant
Hixson-Crowell 
dissolution rate 
constant
Free OCT
Free CTX 0.428r2 = 0.826
0.0397
r2 = 0.933
5.153
r2 = 0.914
0.428
r2 = 0.976
CTX-OCT-beads (OCT abs) 0.352r2 = 0.904
0.009
r2 = 0.949
6.806
r2 = 0.918
0.244
r2 = 0.934
CTX-OCT-beads (CTX abs) 0.215r2 = 0.808
0.003
r2 = 0.850
4.312
r2 = 0.848
0.106
r2 = 0.891
Table 3. Rate constants and correlation coefficients for all formulations using zero-order, first-order, Higuchi, 
and Hixson-Crowell equations. Free OCT = free octreotide, Free CTX = free cetuximab, CTX-OCT-beads 
(OCT abs) = cetuximab-octreotide beads depending on the absorbance of octreotide, CTX-OCT-beads (CTX 
abs) = cetuximab-octreotide beads depending on the absorbance of cetuximab.
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human hepatocellular carcinoma cell line (HepG-2), and colon carcinoma cell line (HCT-116) were obtained 
from VACSERA-Cell Culture Unit (Cairo, Egypt). RPMI-1640 medium, SRB (SulphoRhodamine-B), DMSO 
(dimethyl sulfoxide), and doxorubicin were purchased from Sigma Co. (St. Louis, USA). Fetal bovine serum was 
Figure 8. Mechanistic diagram of the CTX-OCT release from Ca-alginate-beads and target the somatostatin 
receptor.
No. Code
IC50 (µg/mL)
HCT-116 HEPG-2 MCF-7
1 Calcium alginate-beads 30.5 ± 2.1 26.7 ± 1.9 32.8 ± 3.1
2 Free OCT 7.92 ± 0.61 10.26 ± 0.97 12.61 ± 0.98
3 Free CTX 5.21 ± 0.44 7.32 ± 0.58 8.59 ± 0.78
4 OCT-alginate-beads 5.48 ± 0.47 5.76 ± 0.48 7.09 ± 0.55
5 CTX-alginate-beads 4.38 ± 0.38 3.82 ± 0.24 5.17 ± 0.42
6 CTX-OCT-Alginate-beads 6.27 ± 0.56 8.13 ± 0.73 8.54 ± 0.76
Table 4. Antiproliferative activity of octreotide, cetuximab, and their formulated Ca-alginate-beads. Free 
OCT = free octreotide, Free CTX = free cetuximab, OCT-alginate-beads = octreotide alginate-beads, CTX-
alginate-beads = cetuximab alginate-beads, CTX-OCT-beads = cetuximab-octreotide beads.
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obtained from Sigma Aldrich (Irvine, UK). All chemicals used in this study were of analytical grade and used as 
received without any further purification. All prepared solutions were prepared with deionized water.
Methodology. Preparation of the conjugated CTX-OCT-Alg. For preparing of Ca-alginate-beads loaded 
with CTX-OCT. A stock solution of sodium alginate was prepared by dissolving 2 g sodium alginate powder in 
100 mL distilled water with the aid of magnetic stirring at 100 rpm for 1 hr52. Six diluted concentrations of sodium 
alginate were prepared at 16 µM, 22 µM, 35 µM, 60 µM, 82 µM, and 128 µM. For preparing of calcium chloride 
solution, one hundred milliliters 0.2 M CaCl2 were prepared by adding 2.22 g to 100 mL water, which was then 
mixed by the aid of magnetic stirring at 100 rpm for 1 min52. Moreover, sodium alginate solution was dropped 
into CaCl2. Each concentration of sodium alginate was dropped into (0.2 M) calcium chloride solution using a 
2-mL pipette and mixed with the aid of magnetic stirring at 100 rpm.
The coating of OCT to CTX depends on their solubility difference in aqueous and organic media; CTX can be 
coated with OCT using the solvent evaporation method53 for SSRT targeting. OCT is a water-soluble drug, while 
CTX is solubilized in 1 mL 1:1 methanol and chloroform mixture. Briefly, each drug was separately mixed with a 
suitable solvent; 30 mg OCT was dissolved in 2.5 mL phosphate buffer and 50 mg CTX was dissolved in 1 mL 1:1 
methanol and chloroform. The mixture was left to mix for 4 hr at 100 rpm to evaporate the methanol and chloro-
form and facilitate the OCT coating of CTX. The reaction produced 8.2 µM CTX that was soluble in water due to 
being coated with 736 µM OCT (Fig. 9).
preparation of ctX-oct-loaded ca-alginate-beads. The conjugated CTX-OCT solution was mixed 
with 128 µM sodium alginate and then dropped into 100 ml 0.2 M CaCl2 using a 2-mL pipette, and stirred at 
100 rpm. The obtained beads were loaded with CTX-OCT. The formulated beads were purified by filtration 
through 90-mm filter paper obtained from Sigma Aldrich (Irvine, UK). Finally, formulated beads were dried in 
an oven at 40 °C for 4 hr (Fig. 9).
Determination of encapsulation efficiency. To determine the drug content/encapsulation efficiency 
of the CTX-OCT-Alg, 10 mg beads were placed in 100 mL phosphate buffer, pH 7.4. The mixture was stirred 
for 6 hr until all beads dissolved and released the CTX-OCT content. The solution was measured for encapsu-
lation efficiency of CTX-OCT using a UV spectrophotometer (Varian Cary® 50 UV-Vis Spectrophotometer, 
Port Melbourne, Australia) at a wavelength of 360 nm, while OCT was measured at 291 nm. Drug content was 
computed using a calibration curve (R2 = 0.9998) prepared from CTX-OCT solutions with concentrations rang-
ing 1–6 µg/mL. The drug loading capacity of the Ca-alginate-beads was calculated according to the following 
equation:
Total amount of drug in particle
weight of particles taken
Drug Loading (%) ( ) 100= ×
The actual concentration of obtained CTX-OCT-Alg was determined by a comparison between the concen-
tration of a known standard and the concentration of unknown sample using different diluted concentrations of 
both CTX and OCT54.
Size measurement. The size of CTX-OCT-Alg were assessed with an optical microscope fitted with a stage 
micrometer using a Leica Ultracut UCT Ultra-microtome (Mannheim, Germany) with the accuracy of 0.5–3 mm. 
Analysis of prepared beads was performed at a resolution of 1.5× to determine the diameter of beads with each 
square equal to 100, and then calculated bead diameter by the number of squares occupied55.
Scanning electron microscopy (SEM). Five milligrams of each empty Ca-alginate and CTX-OCT-Alg 
were milled into a fine powder with a mortar and pestle. SEM was carried out using a JEOL JSM-550 Scanning 
Electron Microscope (Jeol, Akishima, Tokyo, Japan) to analyze the superficial morphology of the formulated bead 
powder. Randomly chosen bead powder samples were placed on the surface double-sided copper conductive tape. 
The beads were then sputter-coated (Sputter coater, JOEL JFC-1300) with a thin layer of platinum in a vacuum 
for 55 s at 25 mÅ using a coating unit to make it electrically conductive before imaging in an SEM instrument56.
Transmission electron microscopy (TEM). A transmission electron microscope (TEM) was used to 
characterize the exterior and interior shape of Ca-alginate-beads particles (FEI Tecnai G2 20 TWIN, USA) that 
was operated at 200 kV. The point-to-point with the resolution of this microscope was less than 0.25 nm, while the 
line-to-line resolution was less than 0.10 nm57.
Differential scanning calorimetry (DSC). To study the thermal behavior of CTX, OCT, CTX-OCT, and 
CTX-OCT-Alg, DSC measurements were conducted using a DSC-60 calorimeter (Shimadzu, Kyoto, Japan)58. 
DSC-60 was used for thermal analysis of CTX-OCT-Alg and their powders, sodium alginate powder and 
ca-alginate-beads. Exactly 5 mg of CTX-OCT-Alg were placed on aluminum pans and assessed for 27 min at 
10 °C per min, and then 5 mg of each raw drug powder was assessed separately under same conditions. The DSC 
thermogram of conjugated CTX-OCT, sodium alginate and CTX-OCT powder was analyzed to confirm the 
materials were pure, confirm conjugation, and to identify any drug-polymer interactions.
Fourier-transform infrared spectroscopy (FTIR). FTIR was used to test the compatibility of all compo-
nents together; therefore, we aimed to detect any drug interaction between the drug and polymer by collecting 
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between 400 and 4000 cm−1. CTX-OCT loaded alginate-bead powder, sodium alginate, OCT powder, and CTX 
powder were subjected to FTIR (Nicolet™ iS50 FTIR Spectrometer, Thermo SCIENTIFIC Co., Twin, USA)32,36.
Swelling percentage. Percentage of swelling was studied by investigating the penetration of HCl or phos-
phate buffer into CTX-OCT-Alg55. Eight beads were tested for their swelling in 50 mL 0.1 HCl for 1 hr followed by 
50 mL phosphate buffer for another 3 h. The swelling % was determined and presented as a graph.
In vitro release of ctX-oct-Alg. In a dissolution tester (Validata–Hansen study Chatsworth, Ca, USA), a 
aliquot of CTX-OCT loaded Ca-alginate-beads equal to 50 mg per medication rotated at 50 rpm. 1 mL sample was 
withdrawn and substituted by 1 mL of phosphate buffer at predefined times. The CTX and OCT published rates 
were measured using UV spectroscopy for 360 nm for CTX and 292 nm for OCT, depending on the calibration 
Figure 9. (a) Physical adsorption of octreotide to cetuximab depends on their different solubilities in aqueous 
media. (b) Formation of Ca-alginate-beads loaded with conjugated of cetuximab-octreotide.
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curve23. The CTX-OCT-Alg were placed in 50 mL 0.1 N HCl (pH 1.2) for 60 min, then the same beads were fil-
tered and retested in phosphate buffer (pH 7.4) for an additional 210 min. The released CTX-OCT from the beads 
was analyzed spectrophotometrically at a wavelength of 360 nm for CTX, measured at 291 nm for OCT.
Cytotoxic activity and antiproliferative activity of the formulae. An in vitro cytotoxicity assay of all 
compounds was evaluated using the method described by Bakr et al.59. The study was performed in three human 
tumor cell lines: Michigan Cancer Foundation-7 (MCF-7), human hepatocellular carcinoma (HepG-2) and colon 
carcinoma (HCT-116). The cells were cultured with 10% fetal bovine serum in RPMI-1640 solution contain-
ing antibiotics (100 units/mL penicillin and 100 μg/mL streptomycin) and seeded in a 96-well plate at 1 × 104 
cell/well density and cultured at 37 °C, 5% CO2, for 48 hr. Cells were loaded with 6.25 and 100 μg/mL of blank 
ca-alginate beads, OCT only, CTX only, OCT alginate beads, CTX alginate beads and CTX-OCT-Alginate beads, 
and were incubated for 24 hr. The medium was discarded and cells were fixed in 150 μL/well 10% trichloroacetic 
acid (TCA) for 1 hr at 4 °C, and subsequently rinsed with water three times. Wells were stained with 70 μL/well 
0.4% SRB for 10 min in the dark at 37 °C. The cells were then washed with 1% acetic acid to remove any unbound 
dye, then air-dried for 24 hr. The dye was solubilized in 50 μL/well 10 mM tris base (PH 7.4) for 5 min on a shaker 
at 1600 rpm. The optical density (OD) of each well was measured spectroscopically at 570 nm with an ELISA 
microplate reader (EXL 800 USA). The inhibitory concentration at 50% (IC50) was determined from an expo-
nential curve of viability versus concentration of CTX and OCT. The viabilities were determined by the variable 
Sigmaplot software (systat software inc) as (A570 of samples/A570 of samples not being treated) × 100 and the 
amount IC50 (the concentration required to inhibit cell viability by 50 percent) for each compound. The data were 
collected and analysed to estimate the cell viability and growth effects of the testing compounds.
conclusions
Targeted drug delivery using specific drug carriers to treat tumors has many benefits including reduction of 
off-site targets and hence side effects, whilst also reducing the dose of the anticancer agent required for therapeu-
tic response. We have successfully produced peptide–drug conjugates (PDCs) to function as potent drug delivery 
carriers due to their simplicity, versatility and relatively low cost for the construction of PDCs. In this study, CTX 
was successfully coated with OCT and loaded into alginate beads (CTX-OCT-Alg). FTIR studies confirmed the 
physical interaction of all components but found no interaction between CTX, OCT and alginate. The in vitro 
release results showed that CTX-OCT-Alg had a low drug release rate after 1 h in 0.1 HCl 1.2 pH, while in phos-
phate buffer pH 7.4, all drug contents were released over 5 h. Our results demonstrate CTX-OCT-Alg beads to 
have excellent gastro-resistant activity and efficiently deliver anti-cancer drugs to the higher pH environments of 
the colon with higher antiproliferative activity compared to free drug.
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